Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Appili Therapeutics Inc (APLI.TO)

Appili Therapeutics Inc (APLI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stocks in play: Appili Therapeutics Inc. Baystreet - Thu Jun 29, 2023

Has entered into a definitive agreement with respect to an unsecured $300,000 bridge loan from Bloom ...

APLI.TO : 0.0350 (-12.50%)
Stocks in play: Appili Therapeutics Inc. Baystreet - Fri Jun 23, 2023

Announced its financial and operational results for the fiscal year ended March 31, 2023. The net loss ...

APLI.TO : 0.0350 (-12.50%)
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer Business Wire - Mon Apr 3, 2023

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023 Business Wire - Tue Feb 14, 2023

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program Business Wire - Tue Jan 17, 2023

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus,...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)
Stocks in play: Appili Therapeutics Inc. Baystreet - Fri Jan 13, 2023

Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance ...

APLI.TO : 0.0350 (-12.50%)
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole Business Wire - Fri Jan 13, 2023

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy Business Wire - Mon Nov 14, 2022

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023 Business Wire - Thu Nov 10, 2022

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders Business Wire - Thu Sep 22, 2022

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0300 (+1.69%)

Barchart Exclusives

Is MicroStrategy Headed for S&P 500 Eligibility? Barchart - 56 minutes ago
MicroStrategy is a tech stock with significant exposure to Bitcoin, tying its share prices to the digital asset. However, one analyst thinks MSTR should be targeting the benchmark S&P 500 Index. Let's see why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot